Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden

[1]  R. Peters,et al.  Long-Term Clopidogrel Therapy in Patients Receiving Percutaneous Coronary Intervention , 2012, PharmacoEconomics.

[2]  B. Heeg,et al.  Oral Antiplatelet Therapy in Secondary Prevention of Cardiovascular Events , 2012, PharmacoEconomics.

[3]  M. Ekman.  Consumption and Production by Age in Sweden : Basic Facts and Health Economic Implications , 2010 .

[4]  D. Fidan,et al.  Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials* , 2008 .

[5]  A. Smala,et al.  Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany , 2008, Current medical research and opinion.

[6]  G. Davı̀,et al.  Platelet activation and atherothrombosis. , 2007, The New England journal of medicine.

[7]  U. Persson,et al.  [Health economics evaluations are of great significance for Pharmaceutical Benefit Board's decisions]. , 2007, Lakartidningen.

[8]  B. Jönsson,et al.  Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials. , 2007, Clinical therapeutics.

[9]  T. Haghfelt,et al.  [Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark]. , 2006, Ugeskrift for laeger.

[10]  C. Mathers,et al.  Stroke incidence and prevalence in Europe: a review of available data , 2006, European journal of neurology.

[11]  E. Dasbach,et al.  Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial , 2004, Journal of hypertension.

[12]  K. Malmberg,et al.  The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden. , 2005, Clinical therapeutics.

[13]  Deepak L. Bhatt,et al.  Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. , 2004, Archives of internal medicine.

[14]  Sonia S Anand,et al.  Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. , 2004, JAMA.

[15]  Anthony J Culyer,et al.  National Institute for Clinical Excellence and its value judgments , 2004, BMJ : British Medical Journal.

[16]  S. Yusuf,et al.  Cost‐effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long‐term model based on the cure trial , 2004, Journal of internal medicine.

[17]  Andrew Briggs,et al.  Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions. , 2004, Health economics.

[18]  H. Tran,et al.  Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. , 2004, Vascular medicine.

[19]  Deepak L. Bhatt,et al.  Benefit of Clopidogrel Over Aspirin Is Amplified in Patients With a History of Ischemic Events , 2004, Stroke.

[20]  E. Glader,et al.  Cost of stroke in Sweden: an incidence estimate. , 2003, International journal of technology assessment in health care.

[21]  L. Annemans,et al.  PCV6 AN ECONOMIC EVALUATION OF CLOPIDOGREL VS. ASPIRIN IN SECONDARY PREVENTION OF ISCHEMIC EVENTS IN HIGH RISKATHEROTHROMBOTIC PATIENTS IN ITALY , 2003 .

[22]  A. Hofman,et al.  Incidence, risk, and case fatality of first ever stroke in the elderly population. The Rotterdam Study , 2003, Journal of neurology, neurosurgery, and psychiatry.

[23]  X. Lenne,et al.  Cost-effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial , 2003 .

[24]  J. Dinet,et al.  PCV1 AN ECONOMIC EVALUATION OF CLOPIDOGREL IN SECONDARY PREVENTION OF ISCHEMIC EVENTS: HIGH RISK POPULATIONS , 2002 .

[25]  M. Ekman.  Studies in health economics : modelling and data analysis of costs and survival , 2002 .

[26]  R. Feachem.  Commission on Macroeconomics and Health. , 2002, Bulletin of the World Health Organization.

[27]  J. Sachs.  Macroeconomics and health: investing in health for economic development , 2002 .

[28]  J Raftery,et al.  NICE: faster access to modern treatments? Analysis of guidance on health technologies , 2001, BMJ : British Medical Journal.

[29]  Grobbee De,et al.  [CBO guideline 'High blood pressure' (revision)]. , 2001 .

[30]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[31]  A. Hoes,et al.  [CBO guideline 'High blood pressure' (revision)]. , 2001, Nederlands tijdschrift voor geneeskunde.

[32]  P. R. R. Ecurrent,et al.  EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .

[33]  A A Tsiatis,et al.  Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. , 2000, Circulation.

[34]  J. Caro,et al.  Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events. , 1999, The American journal of medicine.

[35]  M. Hiatt.  Thrombolytic Therapy with Streptokinase and Tissue Plasminogen Activator in a Patient with Suspected Acute Myocardial Infarction: A Decision Analysis , 1999, Cardiology.

[36]  S. Hallan,et al.  Quality of life after cerebrovascular stroke: a systematic study of patients’ preferences for different functional outcomes , 1999, Journal of internal medicine.

[37]  N. Zethraeus,et al.  Costs of coronary heart disease and stroke: the case of Sweden , 1999, Journal of internal medicine.

[38]  G. Samsa,et al.  Epidemiology of recurrent cerebral infarction: a medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost. , 1999, Stroke.

[39]  J. Oehlert,et al.  Cost-Effectiveness of Screening for Carotid Stenosis in Asymptomatic Persons , 1997, Annals of Internal Medicine.

[40]  David O. Meltzer,et al.  Accounting for future costs in medical cost-effectiveness analysis. , 1997 .

[41]  M. Dennis.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .

[42]  David Schultz,et al.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.

[43]  H Wedel,et al.  Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S) , 1996, European heart journal.

[44]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[45]  Erry,et al.  Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. , 1995, The New England journal of medicine.

[46]  L Goldman,et al.  Stability of Time-tradeoff Utilities in Survivors of Myocardial Infarction , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.